Adult Dosing

Persistent facial erythema of rosacea

• Apply a pea-size amount once daily to each of the five areas of the face (forehead, chin, nose, each cheek) avoiding the eyes and lips

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Use cautiously in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sjögren’s syndrome
• Alpha-2 adrenergic agonists can lower blood pressure. Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease
• Accidental ingestion of topical gel may lead to serious adverse reactions such as lethargy, respiratory distress with apneic episodes (requiring intubation), sinus bradycardia, confusion, psychomotor hyperactivity, and diaphoresis
• Keep topical gel out of reach of children
• Intermittent flushing occurred in some subjects treated with topical gel. Erythema and flushing appeared to resolve after discontinuation of therapy

Pregnancy Category:B

Breastfeeding: It is not known whether brimonidine tartrate is excreted in human milk, although in animal studies, brimonidine tartrate has been shown to be excreted in breast milk. Because of the potential for serious adverse reactions from topical gel in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

• DERM: Erythema, flushing, skin burning sensation, dermatitis contact, paraesthesia, acne, pain of skin
• EENT: Vision blurred, nasal congestion, nasopharyngitis
• MISC: Increased intraocular pressure, headache

• Selective alpha-2 adrenergic agonist; reduces erythema through direct vasoconstriction
• Extensively metabolized by Liver
• Renally excreted
• Half-life: Unknown

US Trade Name(s)

• Mirvaso

US Availability

Mirvaso

• GEL: 0.33 %

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Dermatologic

Dermatologic Topical Agents

Miscellaneous Agents